Ovarian cancer: Emerging molecular-targeted therapies

Citations of this article
Mendeley users who have this article in their library.


With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients. © 2012 Sourbier.




Sourbier, C. (2012). Ovarian cancer: Emerging molecular-targeted therapies. Biologics: Targets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/btt.s24155

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free